New study results show promise for cannabidiol (CBD) as a treatment for Parkinson’s disease and traumatic brain injuries.
Today, San Diego-based Medical Marijuana Inc. (MMI) announced its subsidiary HempMeds’ role in the studies.
The goal was to demonstrate CBD’s effectiveness in treating Parkinson’s disease.
MMI is participating in another study exploring how CBD may reduce extracellular glutamate levels, which can lead to brain injuries.
The study is in collaboration with the Center for Research and Advanced Studies of Neurological Diseases at the Siglo XXI National Medical Center.
Dr. Luisa Rocha led the study in conjunction with a group of Mexican scientists.
MMI says the study demonstrated the efficacy of its RSHO CBD oil in treating traumatic brain injuries.
“Through this controlled study, we were able to observe that the oral administration of cannabidiol during the seven days prior to an injury helped to avoid the over-release of glutamate that results from brain trauma,” says Dr. Rocha. “It was also shown that the application of CBD helps sensorimotor improvement.”
Glutamate is the central nervous system’s primary excitatory neurotransmitter.
When glutamate levels are abnormally high, it causes excitotoxicity and can lead to neuron death.
Dr. Rocha says the study results increased comprehension of how CBD helps reduce traumatic brain injury-induced excitotoxicity and improve recovery.
According to Dr. Rocha, the CBD treatments were sufficient for lessening traumatic brain injury aftermath.
“Clinically proving the therapeutic potential of CBD is at the core for our Company’s ethos, and the results of this study further proves the therapeutic value of plant based CBD,” says MMI CEO Blake Schroeder. “Through our research initiatives, we continue to prove how CBD can positively affect patients worldwide. While federally funded research institutions in the US have been slow to embrace cannabis-based research, Latin American institutions have been performing this type of research in conjunction with our Company for years.”
Schroeder says MMI will continue research in Mexico and Brazil as it pursues pharmaceutical registration for its products.
The study used MMI’s Real Scientific Hemp Oil (RSHO), which has a high CBD concentration and no THC.